AbbVie Options AND Gated Bispecific Programs From DISCO

DISCO Pharmaceuticals announced a research and option-to-license collaboration with AbbVie on November 19. DISCO receives $40 million upfront and may receive up to $2.5 billion in option, development and other milestone payments plus royalties;…




